SPI-M-O Medium-Term Projections

4th August 2021

SPI-M-O Medium-term Projections

- These projections are not forecasts or predictions. They represent a scenario in which the trajectory of the epidemic continues to follow the trends that were seen in the data up to 2nd August.
- The delay between infection, developing symptoms, the need for hospital care, and death means they cannot fully reflect the impact of policy and behavioural changes made in the two to three weeks prior to 2nd August.
- The projections do not include the effects of any future policy or behavioural changes. The effect of school opening and closing has been included.
- The projections include the impact of vaccines given over the next three weeks. This has been based on a rollout scenario provided by Cabinet Office for modelling purposes. The rollout of these doses will have limited impact over this timescale, given lags between vaccination and protection, and between infection and hospital admission.
- The projections assume vaccinations are administered according to JCVI's priority order, with uptake in the over 40-year olds based on the number of vaccines given to date and uptake in those aged 40 and under assumed to be 80%.
- Modelling groups have used their expert judgement and evidence from <u>Public Health England</u>, <u>Scottish Universities & Public Health Scotland</u>, and other published efficacy studies when making assumptions about vaccine effectiveness. A table summarising these assumptions is available in the annex.
- The number of deaths have fallen to very low levels in some nations and regions. Projecting forwards is difficult when numbers fall to very low levels, therefore SPI-M-O have decided to pause producing medium-term projections in areas where this is the case. The small numbers can also introduce apparent inconsistency as regions are aggregated.
- Not all modelling groups produce projections for both hospitalisations and deaths so there will be some differences between the models included in the combined projections for each metric.


Metrics:

- **New hospitalisations per day:** Number of individuals admitted with COVID-19 and inpatients newly diagnosed with COVID-19. Data definitions differ slightly across all four nations.
- New deaths per day (by date of death): The number of COVID-19 deaths within 28 days of a positive test. Data definitions differ slightly across all four nations.


New hospital admissions per day

These projections are based on current trends and will not fully reflect the impact of policy or behavioural changes over the past two to three weeks. They are not forecasts or predictions.


ENGLAND



WALES



SCOTLAND



NORTHERN IRELAND

SPI-M do not believe this week's projections are an accurate reflection of the future trajectory of hospital admissions in Northern Ireland.

Key

• Real data

Expected to Increase

Projection Midpoint

High and low estimates
5th to 95th percentile

High and low estimates
25th to 75th percentile

Models

The fan charts show the **90% credible** interval and interquartile range of the combined projections based on current trends.

The delay between infection, developing symptoms, the need for hospital care, and death means they cannot fully reflect the impact of policy or behavioural changes in the two to three weeks prior to 2nd August.

These projections include the potential impact of vaccines to be given over the next three weeks. This has been based on a rollout scenario provided by Cabinet Office for modelling purposes; with uptake in the over 40-year olds based on the number of vaccines given to date and uptake in those aged 40 and under assumed to be 80%. These doses will have a limited impact over this timescale, given lags between vaccination and protection, and between infection and hospital admission.

The projections do not include the effects of any future policy or behavioural changes.

Data notes:

England: Number of patients admitted with confirmed COVID-19 and the number of inpatients diagnosed with COVID-19 in the past 24 hours. Taken from NHSE COVID-19


Wales: Number of patients admitted with confirmed COVID-19 and inpatients diagnosed with COVID-19. Provided by Public Health Wales.

Scotland: Number of patients who tested positive for COVID-19 in the 14 days prior to admission, on the day of admission, or during their stay in hospital. Readmissions within 14 days of a positive test are excluded. Provided by Public Health Scotland.

Northern Ireland: Number of patients admitted with confirmed COVID-19 and inpatients diagnosed with COVID-19. Provided by Health and Social Care Northern Ireland.

New hospital admissions per day

These projections are based on current trends and will not fully reflect the impact of policy or behavioural changes over the past two to three weeks. They are not forecasts or predictions.



Projection Midpoint High and low estimates 5th to 95th percentile High and low estimates 25th to 75th percentile Models

Expected to Increase

Real data

Key

The fan charts show the 90% credible interval and interquartile range of the combined projections based on current trends.

The delay between infection, developing symptoms, the need for hospital care, and death means they cannot fully reflect the impact of policy or behavioural changes in the two to three weeks prior to 2nd August.

These projections include the potential impact of vaccines to be given over the next three weeks. This has been based on a rollout scenario provided by Cabinet Office for modelling purposes; with uptake in the over 40-year olds based on the number of vaccines given to date and uptake in those aged 40 and under assumed to be 80%. These doses will have a limited impact over this timescale, given lags between vaccination and protection, and between infection and hospital admission.


The projections do not include the effects of any future policy or behavioural changes.

COVID-19 and the number of inpatients diagnosed with COVID-19 in the past 24 hours. The past data is taken from the NHS England COVID-19 Sitreps.

New deaths per day

These projections are based on current trends and will not fully reflect the impact of policy or behavioural changes over the past two to three weeks. They are not forecasts or predictions.

ENGLAND



Due to an insufficient number of projections it hasn't been possible to produce a reliable combined projection for the number of deaths in Scotland, Wales and Northern Ireland this week.

Real data Expected to Increase Projection Midpoint High and low estimates 5th to 95th percentile High and low estimates 25th to 75th percentile Models

The fan charts show the **90% credible interval and interquartile range** of the combined projections based on current trends.

The delay between infection, developing symptoms, the need for hospital care, and death means they cannot fully reflect the impact of policy or behavioural changes in the two to three weeks prior to 2nd August.

These projections include the potential impact of vaccines to be given over the next three weeks. This has been based on a rollout scenario provided by Cabinet Office for modelling purposes; with uptake in the over 40-year olds based on the number of vaccines given to date and uptake in those aged 40 and under assumed to be 80%. These doses will have a limited impact over this timescale, given lags between vaccination and protection, and between infection and hospital admission.

The projections do not include the effects of any future policy or behavioural changes.

Data Notes:

The number of COVID-19 deaths (by date of death) within 28 days of a positive test.

The past data for England is taken from the PHE line list of deaths. The past data for Scotland, Wales, and Northern Ireland is taken from the Coronavirus (COVID-19) in the UK dashboard on Gov.uk.

New deaths per day

These projections are based on current trends and will not fully reflect the impact of policy or behavioural changes over the past two to three weeks. They are not forecasts or predictions.

LONDON

SPI-M's consensus view is that the number of deaths in London will remain low over the next three weeks.

EAST OF ENGLAND


SPI-M's consensus view is that the number of deaths in the East of England will remain low over the next three weeks.

MIDLANDS 25 20 15 10 10 11/107 18/07 25/07 01/20me 06/08 15/08 22/08


SOUTH EAST

SPI-M's consensus view is that the number of deaths in the South East will remain low over the next three weeks.





NORTH WEST



SOUTH WEST

SPI-M's consensus view is that the number of deaths in the South West will remain low over the next three weeks.

Key



Expected to Increase



High and low estimates 25th to 75th percentile

Models

The fan charts show the **90% credible** interval and interquartile range of the combined projections based on current trends.

The delay between infection, developing symptoms, the need for hospital care, and death means they cannot fully reflect the impact of policy or behavioural changes in the two to three weeks prior to 2nd August.

These projections include the potential impact of vaccines to be given over the next three weeks. This has been based on a rollout scenario provided by Cabinet Office for modelling purposes; with uptake in the over 40-year olds based on the number of vaccines given to date and uptake in those aged 40 and under assumed to be 80%. These doses will have a limited impact over this timescale, given lags between vaccination and protection, and between infection and hospital admission.

The projections do not include the effects of any future policy or behavioural changes.

Data Notes:

The number of COVID-19 deaths (by date of death) within 28 days of a positive test. The past data for England is taken from the PHE line list of deaths.

Annex: SPI-M-O Vaccine Effectiveness Assumptions

| Table 1: Vaccine reduction in risk of hospitalisation or death [3] | | | | | | | | |
|--|---------|-------------------------|----------------------------------|-------------------|------------------------|----------------------------------|-----------------------|-------------------------------|
| | | Imperial [2] (Death) | Imperial [2] (Severe disease) | Manchester [1] | Warwick [2] (Death) | Warwick [2] (Hospitalisation) | PHE/ Cambridge [2] | Scottish Government [2] |
| Pfizer- BioNTech | 1 Dose | 85% | 85% | 75% | 90% | 90% | 78% | 91% |
| | 2 Doses | 95% | 95% | 75% | 98% | 98% | 97% | 98% |
| Oxford- AstraZeneca | 1 Dose | 80% | 80% | 75% | 81% | 81% | 78% | 88% |
| | 2 Doses | 95% | 90% | 75% | 95% | 94% | 97% | 98% |
| Moderna | 1 Dose | 85% | 85% | 75% | 90% | 90% | 78% | 90% |
| | 2 Doses | 95% | 95% | 75% | 98% | 98% | 97% | 98% |

| Table 2: Vaccine reduction in risk of infection [3] | | | | | | | | |
|---|---------|--------------|----------------|-------------|-----------------------|----------------------------|--|--|
| | | Imperial [2] | Manchester [1] | Warwick [2] | PHE/ Cambridge [2] | Scottish Government [2] | | |
| Pfizer-BioNTech | 1 Dose | 33% | 75% | 56% | 31% | 68% | | |
| | 2 Doses | 85% | 75% | 80% | 80% | 90% | | |
| Oxford- AstraZeneca | 1 Dose | 33% | 75% | 34% | 31% | 62% | | |
| | 2 Doses | 58% | 75% | 64% | 80% | 78% | | |
| Moderna | 1 Dose | 33% | 75% | 56% | 31% | 68% | | |
| | 2 Doses | 85% | 75% | 80% | 80% | 90% | | |

| Table 3: Vaccine reduction in onward transmission, in addition to reduction from lower infection risk [3] | | | | | | | | |
|---|---------|--------------|----------------|-------------|-------------------------|------------------------------|--|--|
| | | Imperial [2] | Manchester [4] | Warwick [2] | PHE/ Cambridge [2,4] | Scottish Government [2,4] | | |
| Pfizer-BioNTech | 1 Dose | 40% | - | 45% | - | - | | |
| | 2 Doses | 40% | - | 45% | - | - | | |
| Oxford- AstraZeneca | 1 Dose | 40% | - | 45% | - | - | | |
| | 2 Doses | 40% | - | 45% | - | - | | |
| Moderna | 1 Dose | 40% | - | 45% | - | - | | |
| | 2 Doses | 40% | - | 45% | - | - | | |

^[1] Manchester's model does not split vaccine effectiveness by vaccine type or different doses.

^[2] Imperial, Warwick, PHE/Cambridge & Scottish Government's vaccine effectiveness assumptions are for the B.1.617.2 (delta) variant.

^[3] The assumed delay between vaccination and protection varies between 10 and 21 days for dose 1 and between 7 and 21 days for dose 2 across the modelling groups.

^[4] The Manchester, PHE/ Cambridge and Scottish Government models do not include a reduction in the risk of onwards transmission after receiving either vaccine.